Status: Recruiting
RTX001 Autologous Engineered Macrophages for Liver Cirrhosis
The purpose of this study is to assess the safety and efficacy of RTX001 in patients with end-stage liver disease. This study is the first time RTX001, a macrophage cell therapy engineered to have an anti-inflammatory and anti-fibrotic effect, will be given to humans.
Participants needed: 30
Trial details
Phase: Phase 1, Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Resolution Therapeutics LimitedUpdated: Jan 28, 2026Locations: 14
Eligibility criteria
Male or female age ≥18-75 years. [+12]
any viral hepatitidies, or [+33]